Sudeep Pharma Limited · NSE:SUDEEPPHRM
Sudeep Pharma — Q2 FY27 Earnings Presentation
41 slides from Sudeep Pharma's earnings presentation, Oct 28, 2026
Slide 1: Exchange intimation letter for Q2FY27 result presentation
Date: 28th October 2026 To, National Stock Exchange of India Limited BSE Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai – 400051 Scrip Code: 544619 Scrip Symbol- SUDEEPPHRM Sub: Q2FY27 - Result Presentation Ref: R
Slide 2: Investor Presentation Sudeep Pharma Limited October 2026
INVESTOR PRESENTATION Sudeep Pharma Limited October 2026 Pharmaceutical Speciality Advanced Delivering Products That Matter. Excipients Ingredients Materials
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sudeep Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Q2 & H1 FY27 Performance Highlights
01 Q2 & H1 FY27 Performance Highlights
Slide 5: MD's Message
MD’s Message “ We are pleased to report our highest-ever quarterly performance in Q2 FY27, with revenue growing 21% year-on- year to Rs 196.7 crore and EBITDA increasing 32% to Rs 73.2 crore. This performance reflects healthy demand across our Pharma, Food & Nutrition and Specialty Ingredients busin
Slide 6: Q2 & H1 FY27 Performance Highlights
Q2 & H1 FY27 Performance Highlights Revenue from Operations* Rs. Cr. EBITDA* & Margin % Rs. Cr. PAT* & Margin % Rs. Cr. 34.1% 37.2% 34.5% 36.1% 28.7% 26.3% 27.1% 26.0% 355.0 287.6 128.1 92.4 78.0 196.7 99.3 162.7 73.2 51.8 46.8 55.5 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY
Slide 7: Key Highlights for the Quarter
Key Highlights for the Quarter Operational Highlights • Delivered the highest-ever quarterly revenue of Rs 196.7 crore, registering 21% YoY growth • Achieved highest-ever quarterly EBITDA of Rs 73.2 crore, growing 32% YoY. • EBITDA margin improved to 37.2%, up approximately 70 bps YoY, supported by
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Crs)* Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Revenue from Operations 196.7 162.7 21% 355.0 287.6 23% Cost of materials consumed 69.5 60.9 126.1 103.3 Employee Expenses 15.6 14.1 30.0 26.3 Other Expenses 38.3 32.2 70.8 58.7 EBITDA 73.2 55.5 32% 128.1
Slide 9: Consolidated Balance Sheet Statement
Consolidated Balance Sheet Statement Assets (Rs. Crs) Sept-26* Mar-26* Equity & Liabilities (Rs. Crs) Sept-26* Mar-26* Non - Current Assets 605.3 550.9 Total Equity 972.8 898.1 Property, plant and equipment 400.6 224.0 Equity share capital 11.3 11.3 Capital work-in-progress 53.8 178.4 Instruments en
Slide 10: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crs)* Sept-26 Sept-25 Net Profit Before Tax 125.3 103.6 Adjustments for: Non -Cash Items / Other Investment or Financial Items 4.3 0.0 Operating profit before working capital changes 129.6 103.6 Changes in working capital (63.5) (66.3) Cash generated
Slide 11: From Mineral Expertise to Battery Innovation
02 From Mineral Expertise to Battery Innovation
Slide 12: Iron Phosphate: Key Building Block in the LFP Battery Value Chain
Iron Phosphate: Key Building Block in the LFP Battery Value Chain Sudeep’s Presence Raw Materials Chemical Intermediates Battery Chemicals Cathode Material Battery Cells End User Industries Phosphate Rock Phosphoric Acid Iron Phosphate LFP Cathode Material LFP Battery Cell Conventional Iron Phosphat
Slide 13: Capacity Expansion & Strategic Validation
Capacity Expansion & Strategic Validation Emerging as a premier reliable non-Chinese supplier for battery-grade iron phosphate PCAM. Manufacturing Scale Global Presence in Dominant Battery Markets Phase 1: 46 28 25,000 MT Active Customers Product Approvals Estimated Project Completion by March 2027
Slide 14: Leveraging Mineral Chemistry Expertise for Battery Chemicals
Leveraging Mineral Chemistry Expertise for Battery Chemicals Key Product Capacity Location End User Industries Iron Phosphate 25,000 MT In Dahej, Gujarat LFP Cells for Energy Storage Phase I and Electric Vehicles Strategically positioned for Global Opportunity FEOC – Compliant Supply Chain meet Leve
Slide 15: Leading Player in the Excipients & Minerals Actives
03 Leading Player in the Excipients & Minerals Actives
Slide 16: Sudeep Pharma at a Glance
Sudeep Pharma at a Glance Technology-led Specialty Ingredients manufacturer serving Years of Expertise in the Pharmaceutical, Food & Nutrition industry 35 vitamins & mineral chemistries* 5 Manufacturing Sites^ Founded in 1989, 3+ decades of experience in Specialty Chemistries Metric Tones (“MT”) For
Slide 17: Journey from Pharma Excipients to Speciality Ingredients Manufacturer
Journey from Pharma Excipients to Speciality Ingredients Manufacturer 1989 2015–2022 2021–2023 2024 2025 Foundation & Early Global Partnerships & Market Innovation and Portfolio Diversification & Ownership Strategic Acquisitions & IPO Operations Entry Expansion Consolidation Readiness 2015 2021 2024
Slide 18: Corporate Structure
Corporate Structure Sudeep Pharma Limited (Holding) Sudeep Nutrition Private Ltd. Sudeep Pharma USA Inc. Sudeep Pharma B.V. Sudeep Advanced Materials (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) (Wholly Owned Subsidiary) 85% Ownership Sudeep Pharma Limited | Investor
Slide 19: One of the World's Leading and Trusted Manufacturer
One of the World’s Leading and Trusted Manufacturer The Start At Present 2020 2021 2023 2024 2025 Ireland Manufacturing Site¹ 5 Manufacturing Sites^ Europe Sales Office – The Netherlands² USA Sales Office - New Jersey² 100+ HQ - Vadodara, Gujarat³ Products 1989 4 Manufacturing Sites, India ⁴ Foundat
Slide 20: Strengths - Core Competencies and USP's
Strengths - Core Competencies and USP’s Innovation Engineered Through Proprietary Technologies Leadership in High Barrier Industry, Diversified Product Portfolio 6 indigenously developed technologies 100+ Products across different verticals Encapsulation | Spray Drying | Granulation | Liposomal Blen
Slide 21: Key Value Propositions
Key Value Propositions Distinguished global customer base with long standing 1 Market Leadership with Diversified Product Portfolio 6 relationships with Key Customers 2 High Entry Barriers 7 Proven Credentials and Leading Accolades Well-Equipped & Regulatory Compliant Manufacturing 3 Facilities 8 Ex
Slide 22: Market Leadership with Diversified Product Portfolio
1. Market Leadership with Diversified Product Portfolio Delivering Products that Matter Pharmaceutical, Food & Nutrition Speciality Ingredients Battery Materials Battery-Grade Iron Phosphate* Mineral Fortificants Fillers Micro-nutrient Premixes Liposomal Ingredients pCAM for LFP (Lithium Iron Phosph
Slide 23: High Entry Barriers
2. High Entry Barriers Cost Split of a Tablet Composition split of a Tablet ~5% Excipients ~95% API ~95% Excipients ~5% API Low Cost but High Functionality Tablet Performance^ Stability of Tablet^ Disintegration & Dissolution^ Product Range Tailored to Meet the Precise Needs of Customers in a High B
Slide 24: Well-Equipped & Regulatory Compliant Manufacturing Facilities
3. Well-Equipped & Regulatory Compliant Manufacturing Facilities Unit I – Nandesari Unit II – Nandesari Set Up 1989 Set Up 2011 12 Production Lines Calcium Carbonate - Powder, Tricalcium Products Phosphate, Dicalcium Phosphate, Iron Phosphate, Products Oxides, Carbonates, Sulphates Magnesium Stearat
Slide 25: Proprietary Technologies
4. Proprietary Technologies Encapsulation Spray Drying Granulation Blending Liposomal Preparation Trituration Expertise In: Extending Product Shelf-life Target, Controlled and Sustained Release Address Taste and Odor Challenges Particle Engineering Enhance Ingredient Bio-Availability Improved Produc
Slide 26: Strong Research & Development Capabilities
5. Strong Research & Development Capabilities R&D Initiatives Assist in^: R&D Expenses (% of Revenue from Operations) 41 R&D Personnel 1.71% 1.96% 1.66% Extending Product Shelf Life & Vitality 0.91% Ensuring Targeted release of Excipients 6 Proprietary Technologies FY23 FY24 FY25 FY26 Undertaking Pa
Slide 27: Distinguished global customer base with long standing relationships
6. Distinguished global customer base with long standing relationships 1,120+ 14 ~100 Countries 8% Single Largest Customer^ Global Fortune 500 companies as Customers served^ Global presence customers^ 25% Top 5 Customers^ 40+ ~7 Years Blue-chip MNCs in Customer Avg. tenure of relationship with 5 bas
Slide 28: Proven Credentials and Leading Accolades
7. Proven Credentials and Leading Accolades Key Awards Key Certifications FRK Manufacturing Customer Centric Excellence Award Business Partner Award By Millers for Nutrition By Abbott Excellence in Innovative Suppliers Summit 2023 Ingredients Award Manufacturing By Herbalife Nutrition By ASSOCHAM Gl
Slide 29: Experienced Board and Senior Management Team
8. Experienced Board and Senior Management Team Promoters & Directors Board Members Mr. Ajay Kandelkar - Director of Operations Mrs. Reshma Suresh Patel (Independent Director) Dairy technology from Dr. Panjabrao Deshmukh KV. 23 years of Graphical Arts Technical Foundation, Pittsburgh. Prior experien
Slide 30: Healthy Improvement in Performance with Disciplined Balance Sheet
9. Healthy Improvement in Performance with Disciplined Balance Sheet Revenue from Operations Rs. Cr. EBITDA & Margin % Rs. Cr. PAT & Margin % Rs. Cr. 20.8% 39.6% 37.8% 34.6% 36.1% 14.5% 29.0% 27.6% 27.1% 26.0% 642.3 502.0 221.9 174.3 428.7 459.3 181.7 190.0 133.2 138.7 355.0 128.1 92.4 89.1 62.3 FY2
Slide 31: Backed by Healthy Growth in End User Industries
10. Backed by Healthy Growth in End User Industries Speciality Ingredients Pharmaceutical Excipients Battery Chemicals Nutritional Encapsulated Micronutrient Granulated Food Ingredients Global Excipients India Excipients Global Market Ingredients Ingredients Ingredients Ingredients Market Size (CY24
Slide 32: Key Growth Levers
Key Growth Levers # Sudeep
Slide 33: Key Capacity Expansion
Key Capacity Expansion Capacity Visibility (in MT)* Key Segments FY25 FY26 FY27 Existing FY28e FY29-30e 1) Pharma, Food & Nutrition 35,000 35,000 86,200 86,200 86,200 - Greenfield Project Addition 51,200 2) Speciality Ingredients 30,000 37,500 37,500 37,500 37,500 - NSS Capacity Addition 7,500 3) Ba
Slide 34: Inorganic Growth – Vitamin & Mineral Blends Business Acquisition
1. Inorganic Growth – Vitamin & Mineral Blends Business Acquisition Integrate Recently Acquired Entities & Continue Evaluating Inorganic Growth Opportunities Acquired 85.00% Engaged in business of manufacturing of vitamin & mineral blends in form May 2025 of dry blends, water soluble blends, oil sol
Slide 35: Organic Growth – New Greenfield Expansion in Pharma, Food & Nutrition
2. Organic Growth – New Greenfield Expansion in Pharma, Food & Nutrition New Pharma, Food and Nutrition Greenfield at Nandesari, Gujarat Capacity 51,200 MT Annually Total Capex ~ 168 Crores INR Location Nandesari GIDC, Vadodara Gujarat Pharmaceutical Excipients, Actives and Food Focused Segment and
Slide 36: Organic Growth - Battery Materials Plant Progressing Well
3. Organic Growth - Battery Materials Plant Progressing Well Construction work at the Dahej Battery Materials Plant is progressing well and remains on track for completion by March 2027. Setting up plant at Dahej, Gujarat • Project cost: Appx. Rs 300 crores • Expect completion by early CY27 • Mode o
Slide 37: Historical Financial Statements
05 Historical Financial Statements
Slide 38: Historical Profit & Loss Statement
Historical Profit & Loss Statement Particulars (Rs. Crs) FY26* FY25 FY24 FY23 Revenue from Operations 642.3 502.0 459.3 428.7 Cost of materials consumed 227.3 164.8 165.3 182.5 Employee Expenses 51.9 38.3 29.4 66.1 Other Expenses 141.2 108.9 82.9 91.1 EBITDA 221.9 190.0 181.7 89.1 EBITDA Margin (%)
Slide 39: Historical Balance Sheet Statement
Historical Balance Sheet Statement Assets (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Equity & Liabilities (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Non - Current Assets 550.9 293.1 238.5 190.1 Total Equity 898.1 493.1 356.0 223.3 Property, plant and equipment 224.0 177.1 167.0 149.4 Equity share capital 11
Slide 40: Historical Cash Flow Statement
Historical Cash Flow Statement Particulars (Rs. Crs) Mar-26* Mar-25 Mar-24 Mar-23 Net Profit Before Tax 228.1 182.8 174.8 86.0 Adjustments for: Non -Cash Items / Other Investment or Financial Items 9.0 15.5 13.5 17.9 Operating profit before working capital changes 237.1 198.3 188.3 103.9 Changes in
Slide 41: Thank You!
Thank You! Company Details: Investor Relations Advisor : Sudeep Pharma Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L24231GJ1989PLC013141 CIN - U74140MH2010PTC204285 Ms. Dimple Mehta – Company Secretary Mr. Shrikant Sangani / Ms. Shaily Patwa E-mail: cs.sudeep@sudeepgroup.com Email - shrikant.sang